North America Colorectal Cancer Treatment Market Size and Forecast (2021 - 2031)

The North America Colorectal Cancer Treatment Market is projected to grow significantly, reaching approximately US$ 9,829.6 million by 2031, up from US$ 7,902.3 million in 2024, reflecting a compound annual growth rate (CAGR) of 3.2% from 2025 to 2031. This market encompasses the United States, Canada, and Mexico, with the US accounting for the majority of the market share due to its high cancer prevalence.

The landscape of colorectal cancer (CRC) treatment in North America is evolving rapidly, influenced by a rising incidence of the disease, particularly among younger adults, and notable advancements in treatment options. While the overall rates of CRC incidence and mortality have decreased in older populations due to enhanced screening and treatment methods, there is a troubling increase in cases and deaths among individuals under 50. This trend has led to a reassessment of screening guidelines, with recommendations now suggesting that average-risk individuals begin screening at age 45. Colorectal cancer remains the third most commonly diagnosed cancer in North America. According to the American Cancer Society's 2024 report, it is estimated that around 104,270 new colon cancer cases and 45,230 new rectal cancer cases will be diagnosed in the US, with lifetime risks of approximately 5% for men and 4.5% for women.

In Canada, there is a concerted effort to enhance screening and treatment, with provincial programs and the adoption of biosimilars contributing to steady market growth. A significant clinical advancement in CRC treatment is the development of dostarlimab, an anti-PD1 immunotherapy. In a Phase II trial for locally advanced dMMR rectal cancer, dostarlimab monotherapy achieved a remarkable 100% complete clinical response rate, allowing patients to avoid surgery and chemotherapy. This breakthrough was highlighted at the 2025 ASCO meeting in Chicago, where all patients in the trial cohort showed no disease following treatment.

Recent FDA approvals have also shaped the market, including Amgen's combination therapy of Lumakras and Vectibix for KRAS-mutant colorectal cancer, which has demonstrated an extension of progression-free survival to 5.6 months compared to 2 months with standard care. Additionally, Takeda's fruquintinib (Fruzaqla) received FDA approval as a targeted oral kinase inhibitor for patients who have progressed after multiple chemotherapy and anti-VEGF/EGFR therapies.

Emerging diagnostic technologies are transforming care delivery in the CRC treatment landscape. Innovations such as liquid biopsy and minimal residual disease (MRD) testing, utilizing platforms like Guardant Reveal, Natera Signatera, and Exact Sciences' Oncodetect, are revolutionizing relapse monitoring by detecting recurrences up to 28 months earlier than traditional imaging methods. North America is witnessing a robust adoption of immunotherapy, precision medicine through biomarker-guided therapy, and MRD diagnostics, alongside a growing approval of targeted agents for specific genetic subtypes.

The North America Colorectal Cancer Treatment Market is segmented by treatment type, age group, and end users. By treatment, the market includes Surgery, Chemotherapy, Immunotherapy, Targeted Therapy, and Others, with Surgery being the dominant segment in 2024. By age group, the market is divided into Below 49 Years, 50 - 64 Years, and Above 65 Years, with the Above 65 Years segment leading in market share. In terms of end users, Hospitals, Specialty Clinics, Home Care, and Others are the categories, with Hospitals holding the largest share in 2024.

The increasing incidence of colorectal cancer is attributed to demographic changes, lifestyle factors, and a rise in early-onset cases, as reflected in recent epidemiological data. The World Health Organization reported that colorectal cancer is expected to remain the third most commonly diagnosed cancer and the second leading cause of cancer death globally, with approximately 1.9 million new cases and over 900,000 deaths annually. In the US, projections indicate around 154,000 new CRC cases and over 52,900 deaths in 2025, accounting for about 8% of all new cancer diagnoses.

The rise in CRC cases among individuals under 50 has been alarming, with incidence rates increasing by about 2% annually since the mid-1990s. This trend is mirrored in several countries, including Australia, South Korea, and the UK. Factors contributing to this increase include unhealthy dietary habits, sedentary lifestyles, obesity, and environmental influences. Screening remains crucial in reducing CRC incidence and mortality, with expanded colonoscopy and stool-based screening contributing to declining rates among older adults.

In response to the rising incidence of early-onset colorectal cancer, clinical guidelines are being updated to lower the recommended screening age to 45, alongside awareness campaigns aimed at educating younger populations about their increasing risk. The North America Colorectal Cancer Treatment Market is poised for growth, driven by these trends and the ongoing need for innovative treatment and prevention strategies.